| Literature DB >> 35718423 |
Bishow B Adhikari1, Scarlet Shi2, Eileen P Dimond3, Nonniekaye Shelburne4, Patrice Desvigne-Nickens5, Lori M Minasian6.
Abstract
Advances in cancer treatments have led to nearly 17 million survivors in the US today. Cardiovascular complications attributed to cancer treatments are the leading cause of morbidity and mortality in cancer survivors. In response, NCI and NHLBI held 2 workshops and issued funding opportunities to strengthen research on cardiotoxicity. A representative portfolio of NIH grants categorizing basic, interventional, and observational projects is presented. Compared with anthracyclines, research on radiation therapy and newer treatments is underrepresented. Multidisciplinary collaborative research that considers the cardiotoxicity stage and optimizes the balance between cardiovascular risk and cancer-treatment benefit might support continued improvements in cancer outcomes.Entities:
Keywords: Cancer therapy; Cancer treatment; Cardiac toxicity; Cardiotoxicity; Cardiovascular complications; Cardiovascular toxicity; Chemotherapy; Radiation injury
Mesh:
Substances:
Year: 2022 PMID: 35718423 PMCID: PMC9328446 DOI: 10.1016/j.hfc.2022.01.001
Source DB: PubMed Journal: Heart Fail Clin ISSN: 1551-7136 Impact factor: 2.828